<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">38588934</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1555-7162</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Apr</Month><Day>06</Day></PubDate></JournalIssue><Title>The American journal of medicine</Title><ISOAbbreviation>Am J Med</ISOAbbreviation></Journal><ArticleTitle>Imbalanced Brain Neurochemicals in Long COVID and ME/CFS: A Preliminary Study Using MRI.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0002-9343(24)00216-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjmed.2024.04.007</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) patients experience multiple complex symptoms, potentially linked to imbalances in brain neurochemicals. This study aims to measure brain neurochemical levels in long COVID and ME/CFS patients as well as healthy controls to investigate associations with severity measures.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Magnetic resonance spectroscopy data were acquired with a 3T Prisma magnetic resonance imaging scanner (Siemens Healthcare, Erlangen, Germany). We measured absolute levels of brain neurochemicals in the posterior cingulate cortex in long COVID (n = 17), ME/CFS (n = 17), and healthy controls (n = 10) using Osprey software. The statistical analyses were performed using SPSS version 29 (IBM, Armonk, NY). Age and sex were included as nuisance covariates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Glutamate levels were significantly higher in patients with long COVID (P = .02) and ME/CFS (P = .017) than in healthy controls. No significant difference was found between the 2 patient cohorts. Additionally, N-acetyl-aspartate levels were significantly higher in long COVID patients (P = .012). Importantly, brain neurochemical levels were associated with self-reported severity measures in long COVID and ME/CFS.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study identified significantly elevated glutamate and N-acetyl-aspartate levels in long COVID and ME/CFS patients compared with healthy controls. No significant differences in brain neurochemicals were observed between the 2 patient cohorts, suggesting a potential overlap in their underlying pathology. These findings suggest that imbalanced neurochemicals contribute to the complex symptoms experienced by long COVID and ME/CFS patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thapaliya</LastName><ForeName>Kiran</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Centre for Neuroimmunology and Emerging Diseases (NCNED), Griffith University, Gold Coast, QLD, Australia. Electronic address: k.thapaliya@griffith.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall-Gradisnik</LastName><ForeName>Sonya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Centre for Neuroimmunology and Emerging Diseases (NCNED), Griffith University, Gold Coast, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eaton-Fitch</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Centre for Neuroimmunology and Emerging Diseases (NCNED), Griffith University, Gold Coast, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eftekhari</LastName><ForeName>Zeinab</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Centre for Advanced Imaging, The University of Queensland, St. Lucia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inderyas</LastName><ForeName>Maira</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Centre for Neuroimmunology and Emerging Diseases (NCNED), Griffith University, Gold Coast, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnden</LastName><ForeName>Leighton</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Centre for Neuroimmunology and Emerging Diseases (NCNED), Griffith University, Gold Coast, QLD, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med</MedlineTA><NlmUniqueID>0267200</NlmUniqueID><ISSNLinking>0002-9343</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Brain neurochemicals</Keyword><Keyword MajorTopicYN="N">Glutamate</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">ME/CFS</Keyword><Keyword MajorTopicYN="N">MRI</Keyword><Keyword MajorTopicYN="N">N-acetyl-aspartate (NAA)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>9</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>9</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>8</Day><Hour>19</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38588934</ArticleId><ArticleId IdType="doi">10.1016/j.amjmed.2024.04.007</ArticleId><ArticleId IdType="pii">S0002-9343(24)00216-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>